The N-terminal pro B-type natriuretic peptide, and risk of dementia and cognitive decline: A 10-year follow-up Study in the general population

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 4, 2016, Pages 356-362

  Mirza, Saira Saeed ^a   De Bruijn, Renée F A G ^a   Koudstaal, Peter J ^a   Van Den Meiracker, Anton H ^a   Franco, Oscar H ^a   Hofman, Albert ^a   Tiemeier, Henning ^a   Ikram, M Arfan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; DEMENTIA; DISEASE ASSOCIATION; EXECUTIVE FUNCTION TEST; FEMALE; FOLLOW UP; HUMAN; LETTER DIGIT SUBSTITUTION TASK; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGIC ASSESSMENT; RISK ASSESSMENT; STROOP TEST; WORD FLUENCY TEST; CARDIOVASCULAR DISEASE; COGNITION DISORDERS; COMPLICATION; CROSS-SECTIONAL STUDY; GENETICS; INCIDENCE; NEUROPSYCHOLOGICAL TEST; PROGNOSIS; PSYCHOLOGY; RISK FACTOR; SOCIOECONOMICS;

AGED; ALZHEIMER DISEASE; BIOMARKERS; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; NATRIURETIC PEPTIDE, BRAIN; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PROGNOSIS; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 84930410292     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-309968     Document Type: Article

References (46)

1. World Health Organization and Alzheimer's Disease International. Dementia-A public health priority. 2012. http://www.who.int/mental-health/publications/dementia-report-2012/en/index.html
2. Forman DE, Cohen RA, Hoth KF, et al. Vascular health and cognitive function in older adults with cardiovascular disease. Artery Res 2008;2:35-43.
3. Jefferson AL, Himali JJ, Beiser AS, et al. Cardiac index is associated with brain aging: the Framingham Heart Study. Circulation 2010;122:690-7.
4. Kelleher RJ, Soiza RL. Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? Am J Cardiovasc Dis 2013;3:197-226.
5. Moser DJ, Miller IN, Hoth KF, et al. Vascular smooth muscle function is associated with initiation and processing speed in patients with atherosclerotic vascular disease. J Int Neuropsychol Soc 2008;14:535-41.
6. Hall C, Stokke O. [Cardiac natriuretic peptides as markers for cardiac disease-where do we stand today?]. Tidsskr Nor Laegeforen 2002;122:2784-6.
7. Jourdain P, Funck F, Bellorini M, et al. [Brain natriuretic peptide, heart failure and elderly patients]. Ann Cardiol Angeiol (Paris) 2003;52:285-9.
8. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68.
9. Rutten JH, Mattace-Raso FU, Steyerberg EW, et al. Amino-terminal pro-B-type natriuretic peptide cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension 2010;55:785-91.
10. Portegies ML, Kavousi M, Leening MJ, et al. N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack: the Rotterdam Study. Eur J Neurol 2015;22:695-701.
11. Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke 2013;44:961-7.
12. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
13. Rutten JH, Mattace-Raso FU, Verwoert GC, et al. Arterial stiffness as determinant of increased amino terminal pro-B-type natriuretic peptide levels in individuals with and without cardiovascular disease - the Rotterdam Study. J Hypertens 2010;28:2061-7.
14. Daniels LB, Laughlin GA, Kritz-Silverstein D, et al. Elevated natriuretic peptide levels and cognitive function in community-dwelling older adults. Am J Med 2011;124:670-8.
15. Feinkohl I, Sattar N, Welsh P, et al. Association of N-terminal pro-brain natriuretic peptide with cognitive function and depression in elderly people with type 2 diabetes. PLoS One 2012;7:e44569.
16. Gunstad J, Poppas A, Smeal S, et al. Relation of brain natriuretic peptide levels to cognitive dysfunction in adults > 55 years of age with cardiovascular disease. Am J Cardiol 2006;98:538-40.
17. Kerola T, Nieminen T, Hartikainen S, et al. B-type natriuretic peptide as a predictor of declining cognitive function and dementia - a cohort study of an elderly general population with a 5-year follow-up. Ann Med 2010;42:207-15.
18. van den Hurk K, Reijmer YD, van den Berg E, et al. Heart failure and cognitive function in the general population: the Hoorn Study. Eur J Heart Fail 2011;13:1362-9.
19. Hofman A, Darwish MS, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol 2013;28:889-926.
20. Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-15.
21. Schrijvers EM, Verhaaren BF, Koudstaal PJ, et al. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 2012;78:1456-63.
22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
23. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
24. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet 2002;359:1309-10.
25. Hoogendam YY, Hofman A, van der Geest JN, et al. Patterns of cognitive function in aging: the Rotterdam Study. Eur J Epidemiol 2014;29:133-40.
26. Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014;349:g4164.
27. D'Agostino RB Sr, Pencina MJ, Massaro JM, et al. Cardiovascular Disease Risk Assessment: Insights from Framingham. Glob Heart 2013;8:11-23.
28. Vegh C, Langmar Z, Szerzo M, et al. [Connections between apolipoprotein E genotypes and the development of cardiovascular diseases]. Orv Hetil 2012;153:2070-6.
29. Jankovic S, Stojisavljevic D, Jankovic J, et al. Association of socioeconomic status measured by education, and cardiovascular health: a population-based cross-sectional study. BMJ Open 2014;4:e005222.
30. Gunstad J, Paul RH, Cohen RA, et al. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry 2007;48:57-61.
31. Jiang T, Yu JT, Tian Y, et al. Epidemiology and etiology of Alzheimer's disease: from genetic to non-genetic factors. Curr Alzheimer Res 2013;10:852-67.
32. Letenneur L, Launer LJ, Andersen K, et al. Education and the risk for Alzheimer's disease: sex makes a difference. EURODEM pooled analyses. EURODEM Incidence Research Group. Am J Epidemiol 2000;151:1064-71.
33. Wiesmann M, Kiliaan AJ, Claassen JA. Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab 2013;33:1696-706.
34. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92.
35. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
36. Kardys I, Knetsch AM, Bleumink GS, et al. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J 2006;152:514-20.
37. Bots ML, Hofman A, de Jong PT, et al. Common carotid intima-media thickness as an indicator of atherosclerosis at other sites of the carotid artery. The Rotterdam Study. Ann Epidemiol 1996;6:147-53.
38. Wieberdink RG, Ikram MA, Hofman A, et al. Trends in stroke incidence rates and stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. Eur J Epidemiol 2012;27:287-95.
39. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
40. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25:1614-19.
41. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541-53.
42. Leening MJ, Kavousi M, Heeringa J, et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 2012;27:173-85.
43. Tranmer BI, Keller TS, Kindt GW, et al. Loss of cerebral regulation during cardiac output variations in focal cerebral ischemia. J Neurosurg 1992;77:253-9.
44. Massaro AR, Dutra AP, Almeida DR, et al. Transcranial Doppler assessment of cerebral blood flow: effect of cardiac transplantation. Neurology 2006;66:124-6.
45. Cujec B, Polasek P, Voll C, et al. Transesophageal echocardiography in the detection of potential cardiac source of embolism in stroke patients. Stroke 1991;22:727-33.
46. Pepi M, Evangelista A, Nihoyannopoulos P, et al. Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2010;11:461-76.